Liu Hongda, Xu Yunfei, Zhang Qun, Yang Hui, Shi Weichen, Liu Zhaochen, Li Kangshuai, Gong Zheng, Ning Shanglei, Li Shuo, Chen Yuxin
Department of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong 250012, China.
Department of Respiratory Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.
Surg Oncol. 2017 Mar;26(1):13-20. doi: 10.1016/j.suronc.2016.12.003. Epub 2016 Dec 8.
Liver metastasis is the leading cause of lethal colorectal cancer (CRC). For patients with early stage CRC, metachronous liver metastasis is the primary risk for poor prognosis. Accordingly, identification of prospective biomarkers for metachronous liver metastasis would be invaluable in evaluating patients' clinical outcomes and developing personal treatment therapy.
Here we investigated the role of transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) in predicting liver metastasis for early stage CRC. To accomplish this goal, a multi-center retrospective study was performed which included three stages: exploration stage (43 patients), identification stage (162 patients) and validation stage (38 patients). TBL1XR1 expression was evaluated using immunohistochemical staining and RT-qPCR. The prognostic significance of TBL1XR1 in both stage IV CRC patients and early stage CRC patients were evaluated by Kaplan-Meier survival analysis and multivariate analysis, respectively.
For stage IV CRC patients, TBL1XR1 expression was correlated with the number of liver metastases (P = 0.036), and high levels of TBL1XR1 in liver metastases indicated poor overall survival (P = 0.028). Moreover, high expressions of TBL1XR1 can serve as a predictor for liver metastasis in early stage CRC patients (P = 0.003).
TBL1XR1 is a promising biomarker for predicting liver metastasis in early stage CRC patients.
肝转移是致死性结直肠癌（CRC）的主要原因。对于早期CRC患者，异时性肝转移是预后不良的主要风险。因此，鉴定异时性肝转移的前瞻性生物标志物对于评估患者的临床结局和制定个性化治疗方案具有重要价值。
在此，我们研究了转导素（β）样1 X连锁受体1（TBL1XR1）在预测早期CRC肝转移中的作用。为实现这一目标，进行了一项多中心回顾性研究，该研究包括三个阶段：探索阶段（43例患者）、鉴定阶段（162例患者）和验证阶段（38例患者）。使用免疫组织化学染色和RT-qPCR评估TBL1XR1表达。分别通过Kaplan-Meier生存分析和多变量分析评估TBL1XR1在IV期CRC患者和早期CRC患者中的预后意义。
对于IV期CRC患者，TBL1XR1表达与肝转移数量相关（P = 0.036），肝转移中TBL1XR1的高水平表明总生存期较差（P = 0.028）。此外，TBL1XR1的高表达可作为早期CRC患者肝转移的预测指标（P = 0.003）。
TBL1XR1是预测早期CRC患者肝转移的有前景的生物标志物。
